drugset
drugset / Trial / NCT03802201

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

NCT03802201 ↗

Phase 2 Completed 63 enrolled Protagonist Therapeutics, Inc.
NaSequentialOpen-labelTreatment

Summary

This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.

Timeline

Start
2018-12-19
Primary completion
2020-07-31
Completion
2020-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rusfertide Peptide 3 mg Subcutaneous
Subject Rusfertide Peptide 10 mg Subcutaneous
Subject Rusfertide Peptide 20 mg Subcutaneous
Subject Rusfertide Peptide 40 mg Subcutaneous
Subject Rusfertide Peptide 80 mg Subcutaneous

Indications

beta thalassemia